Insider Trading activities of Intra-cellular Thera38, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Intra-cellular Thera38, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Intra-cellular Thera38, Inc. since year 2005. Table 2 shows the detailed insider transactions of Intra-cellular Thera38, Inc. since 2005. The reporting company's ticker symbol is ITCI. The reporting company's CIK number is 1567514.
The total value of stock buying since 2005 is $26,021,828.
The total value of stock sales since 2005 is $16,439,386.
The total value of stock option exercises since 2005 is $672,046.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Intra-cellular Thera38, Inc. (ITCI).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2018-11 0 $0 32,000 $581,579 0 $0
2018-10 0 $0 0 $0 12,500 $18,750
2018-02 0 $0 49,700 $995,164 0 $0
2018-01 0 $0 55,715 $970,830 41,521 $0
2017-12 2,295 $33,230 7,650 $115,380 14,257 $18,750
2017-11 10,000 $155,500 0 $0 0 $0
2017-10 774,195 $12,000,021 18,750 $295,312 18,750 $28,125
2017-01 0 $0 8,400 $139,108 109,370 $242,155
2016-12 195,000 $3,172,491 9,375 $142,921 20,507 $27,243
2016-11 102,000 $1,478,898 0 $0 0 $0
2016-02 0 $0 0 $0 10,000 $13,600
2015-12 0 $0 189,200 $10,162,328 111,250 $134,623
2015-11 0 $0 5,000 $275,000 5,000 $3,000
2015-09 0 $0 0 $0 12,500 $17,000
2015-08 0 $0 10,200 $309,060 0 $0
2015-06 0 $0 25,000 $671,000 0 $0
2015-05 0 $0 0 $0 47,500 $58,900
2015-03 250,000 $6,000,000 0 $0 27,500 $24,900
2015-01 0 $0 5,000 $95,000 0 $0
2014-12 4,266 $62,922 22,500 $375,976 37,200 $18,600
2014-11 175,694 $2,618,774 35,000 $516,250 50,000 $25,000
2014-10 0 $0 30,000 $450,000 0 $0
2014-09 0 $0 5,300 $79,500 300 $150
2014-07 0 $0 0 $0 37,500 $18,750
2014-06 0 $0 15,742 $100,008 0 $0
2014-05 0 $0 11,000 $164,970 37,500 $18,750
2014-02 28,571 $499,992 0 $0 0 $0
2013-12 0 $0 0 $0 12,500 $3,750

Table 2. Detailed insider stock purchases, sales, and option exercises of Intra-cellular Thera38, Inc. insiders (ITCI)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2018-11-12 Marcus Joel S (Director) Sale 7,000 17.94 125,580
2018-11-09 Marcus Joel S (Director) Sale 25,000 18.24 455,999
2018-10-22 Lerner Richard A (Director) Option Ex 12,500 1.50 18,750
2018-02-16 Hineline Lawrence J. (VP of Finance CFO) Sale 16,319 20.01 326,543
2018-02-15 Hineline Lawrence J. (VP of Finance CFO) Sale 33,381 20.03 668,621
2018-01-22 Halstead Michael (SVP and General Counsel) Sale 25,500 18.03 459,765
2018-01-08 Mates Sharon (Chairman, President & CEO) Sale 6,604 17.48 115,437
2018-01-08 Vanover Kimberly E. (SVP, Clinical Development) Sale 772 17.46 13,479
2018-01-05 Mates Sharon (Chairman, President & CEO) Sale 11,257 17.08 192,269
2018-01-05 Hineline Lawrence J. (VP of Finance CFO) Sale 1,870 17.49 32,706
2018-01-05 Vanover Kimberly E. (SVP, Clinical Development) Sale 1,185 17.37 20,583
2018-01-05 Halstead Michael (SVP and General Counsel) Sale 1,560 17.49 27,284
2018-01-04 Mates Sharon (Chairman, President & CEO) Option Ex 6,604 .00 0
2018-01-04 Hineline Lawrence J. (VP of Finance CFO) Sale 3,192 15.67 50,018
2018-01-04 Hineline Lawrence J. (VP of Finance CFO) Option Ex 3,108 .00 0
2018-01-04 Vanover Kimberly E. (SVP, Clinical Development) Option Ex 1,554 .00 0
2018-01-04 Halstead Michael (SVP and General Counsel) Sale 2,660 15.75 41,895
2018-01-04 Halstead Michael (SVP and General Counsel) Option Ex 3,108 .00 0
2018-01-04 Davis Robert E (SVP, Chief Scientific Officer) Sale 1,115 15.60 17,394
2018-01-03 Mates Sharon (Chairman, President & CEO) Option Ex 11,257 .00 0
2018-01-03 Hineline Lawrence J. (VP of Finance CFO) Option Ex 5,297 .00 0
2018-01-03 Vanover Kimberly E. (SVP, Clinical Development) Option Ex 2,648 .00 0
2018-01-03 Halstead Michael (SVP and General Counsel) Option Ex 5,297 .00 0
2018-01-03 Davis Robert E (SVP, Chief Scientific Officer) Option Ex 2,648 .00 0
2017-12-29 Lerner Richard A (Director) Buy 949 14.48 13,741
2017-12-29 Van Nostrand Robert L (Director) Buy 345 14.48 4,995
2017-12-29 Riggs Rory B (Director) Buy 1,001 14.48 14,494
2017-12-11 Lerner Richard A (Director) Sale 7,000 15.09 105,630
2017-12-11 Lerner Richard A (Director) Option Ex 12,500 1.50 18,750
2017-12-05 Davis Robert E (SVP, Chief Scientific Officer) Sale 650 15.00 9,750
2017-12-04 Davis Robert E (SVP, Chief Scientific Officer) Option Ex 1,757 .00 0
2017-11-22 Alafi Christopher D (Director) Buy 10,000 15.55 155,500
2017-10-30 Mates Sharon (Chairman, President & CEO) Sale 18,750 15.75 295,312
2017-10-30 Mates Sharon (Chairman, President & CEO) Option Ex 18,750 1.50 28,125
2017-10-02 Alafi Christopher D (Director) Buy 258,065 15.50 4,000,007
2017-10-02 Alafi Capital Co Llc (10% Owner) Buy 258,065 15.50 4,000,007
2017-10-02 Alafi Moshe (10% Owner) Buy 258,065 15.50 4,000,007
2017-01-26 Marcus Joel S (Director) Option Ex 95,000 2.55 242,155
2017-01-05 Mates Sharon (Chairman, President & CEO) Sale 4,081 16.55 67,540
2017-01-05 Hineline Lawrence J. (VP of Finance CFO) Sale 1,918 16.58 31,800
2017-01-05 Vanover Kimberly E. (SVP, Clinical Development) Sale 800 16.59 13,272
2017-01-05 Halstead Michael (SVP and General Counsel) Sale 1,601 16.55 26,496
2017-01-04 Mates Sharon (Chairman, President & CEO) Option Ex 6,603 .00 0
2017-01-04 Hineline Lawrence J. (VP of Finance CFO) Option Ex 3,107 .00 0
2017-01-04 Vanover Kimberly E. (SVP, Clinical Development) Option Ex 1,553 .00 0
2017-01-04 Halstead Michael (SVP and General Counsel) Option Ex 3,107 .00 0
2016-12-15 Vanover Kimberly E. (SVP, Clinical Development) Sale 9,375 15.24 142,921
2016-12-15 Vanover Kimberly E. (SVP, Clinical Development) Option Ex 18,750 1.45 27,243
2016-12-07 Alafi Christopher D (Director) Buy 20,826 16.14 336,048
2016-12-07 Alafi Capital Co Llc (10% Owner) Buy 20,826 16.14 336,048
2016-12-07 Alafi Moshe (10% Owner) Buy 20,826 16.14 336,048
2016-12-06 Alafi Christopher D (Director) Buy 44,174 16.33 721,449
2016-12-06 Alafi Capital Co Llc (10% Owner) Buy 44,174 16.33 721,449
2016-12-06 Alafi Moshe (10% Owner) Buy 44,174 16.33 721,449
2016-12-04 Davis Robert E (SVP, Chief Scientific Officer) Option Ex 1,757 .00 0
2016-11-14 Alafi Christopher D (Director) Buy 34,000 14.50 492,966
2016-11-14 Alafi Capital Co Llc (10% Owner) Buy 34,000 14.50 492,966
2016-11-14 Alafi Moshe (10% Owner) Buy 34,000 14.50 492,966
2016-02-18 Lerner Richard A (Director) Option Ex 10,000 1.36 13,600
2015-12-15 Hineline Lawrence J. (VP of Finance CFO) Sale 22,500 51.97 1,169,212
2015-12-15 Hineline Lawrence J. (VP of Finance CFO) Option Ex 35,000 1.45 50,855
2015-12-14 Hineline Lawrence J. (VP of Finance CFO) Sale 22,500 51.36 1,155,667
2015-12-14 Hineline Lawrence J. (VP of Finance CFO) Option Ex 7,500 .60 4,500
2015-12-11 Mates Sharon (Chairman, President & CEO) Sale 51,500 54.29 2,796,089
2015-12-11 Mates Sharon (Chairman, President & CEO) Option Ex 68,750 1.15 79,268
2015-12-08 Marcus Joel S (Director) Sale 22,700 54.80 1,243,960
2015-12-07 Marcus Joel S (Director) Sale 40,000 52.97 2,118,600
2015-12-04 Marcus Joel S (Director) Sale 30,000 55.96 1,678,800
2015-11-24 Hineline Lawrence J. (VP of Finance CFO) Sale 5,000 55.00 275,000
2015-11-24 Hineline Lawrence J. (VP of Finance CFO) Option Ex 5,000 .60 3,000
2015-09-09 Fienberg Allen A. (VP of Business Development) Option Ex 12,500 1.36 17,000
2015-08-21 Fienberg Allen A. (VP of Business Development) Sale 200 30.30 6,060
2015-08-19 Fienberg Allen A. (VP of Business Development) Sale 10,000 30.30 303,000
2015-06-08 Wennogle Lawrence P. (Vice President, Drug Discovery) Sale 25,000 26.84 671,000
2015-05-19 Wennogle Lawrence P. (Vice President, Drug Discovery) Option Ex 47,500 1.24 58,900
2015-03-31 Fienberg Allen A. (VP of Business Development) Option Ex 12,500 .60 7,500
2015-03-31 Marcus Joel S (Director) Option Ex 15,000 1.16 17,400
2015-03-11 Sosland Morton I. (10% Owner) Buy 250,000 24.00 6,000,000
2015-01-14 Fienberg Allen A. (VP of Business Development) Sale 5,000 19.00 95,000
2014-12-09 Hineline Lawrence J. (VP of Finance CFO) Sale 11,535 16.52 190,558
2014-12-08 Hineline Lawrence J. (VP of Finance CFO) Sale 10,965 16.91 185,418
2014-12-02 Hineline Lawrence J. (VP of Finance CFO) Option Ex 37,200 .50 18,600
2014-12-01 Alafi Christopher D (Director) Buy 1,422 14.75 20,974
2014-12-01 Alafi Capital Co Llc (10% Owner) Buy 1,422 14.75 20,974
2014-12-01 Alafi Moshe (10% Owner) Buy 1,422 14.75 20,974
2014-11-28 Mates Sharon (Chairman, President & CEO) Sale 35,000 14.75 516,250
2014-11-28 Alafi Christopher D (Director) Buy 35,000 14.75 516,250
2014-11-28 Alafi Capital Co Llc (10% Owner) Buy 35,000 14.75 516,250
2014-11-28 Alafi Moshe (10% Owner) Buy 35,000 14.75 516,250
2014-11-25 Mates Sharon (Chairman, President & CEO) Option Ex 50,000 .50 25,000
2014-11-19 Alafi Christopher D (Director) Buy 1,034 14.25 14,734
2014-11-19 Alafi Capital Co Llc (10% Owner) Buy 1,034 14.25 14,734
2014-11-19 Alafi Moshe (10% Owner) Buy 1,034 14.25 14,734
2014-11-18 Alafi Christopher D (Director) Buy 3,531 14.23 50,246
2014-11-18 Alafi Capital Co Llc (10% Owner) Buy 3,531 14.23 50,246
2014-11-18 Alafi Moshe (10% Owner) Buy 3,531 14.23 50,246
2014-11-14 Alafi Christopher D (Director) Buy 133 15.07 2,004
2014-11-14 Alafi Capital Co Llc (10% Owner) Buy 133 15.07 2,004
2014-11-14 Alafi Moshe (10% Owner) Buy 133 15.07 2,004
2014-11-13 Alafi Christopher D (Director) Buy 2,200 15.12 33,264
2014-11-13 Alafi Capital Co Llc (10% Owner) Buy 2,200 15.12 33,264
2014-11-13 Alafi Moshe (10% Owner) Buy 2,200 15.12 33,264
2014-11-12 Alafi Christopher D (Director) Buy 5,000 15.23 76,150
2014-11-12 Alafi Capital Co Llc (10% Owner) Buy 5,000 15.23 76,150
2014-11-12 Alafi Moshe (10% Owner) Buy 5,000 15.23 76,150
2014-11-11 Alafi Christopher D (Director) Buy 5,000 15.55 77,750
2014-11-11 Alafi Capital Co Llc (10% Owner) Buy 5,000 15.55 77,750
2014-11-11 Alafi Moshe (10% Owner) Buy 5,000 15.55 77,750
2014-11-06 Halstead Michael (SVP and General Counsel) Buy 13,000 15.47 201,110
2014-11-05 Halstead Michael (SVP and General Counsel) Buy 7,000 15.21 106,470
2014-10-16 Wennogle Lawrence P. (Vice President, Drug Discovery) Sale 5,152 15.00 77,280
2014-10-15 Wennogle Lawrence P. (Vice President, Drug Discovery) Sale 2,004 15.00 30,060
2014-10-13 Wennogle Lawrence P. (Vice President, Drug Discovery) Sale 1,600 15.00 24,000
2014-10-08 Wennogle Lawrence P. (Vice President, Drug Discovery) Sale 4,745 15.00 71,175
2014-10-06 Wennogle Lawrence P. (Vice President, Drug Discovery) Sale 636 15.00 9,540
2014-10-03 Wennogle Lawrence P. (Vice President, Drug Discovery) Sale 15,863 15.00 237,945
2014-09-15 Wennogle Lawrence P. (Vice President, Drug Discovery) Sale 5,000 15.00 75,000
2014-09-08 Hineline Lawrence J. (VP of Finance CFO) Sale 300 15.00 4,500
2014-09-08 Hineline Lawrence J. (VP of Finance CFO) Option Ex 300 .50 150
2014-07-21 Wennogle Lawrence P. (Vice President, Drug Discovery) Option Ex 37,500 .50 18,750
2014-06-19 Alafi Moshe (10% Owner) Sale 15,742 6.35 100,008
2014-05-28 Fienberg Allen A. (VP of Business Development) Option Ex 37,500 .50 18,750
2014-05-27 Wennogle Lawrence P. (Vice President, Drug Discovery) Sale 5,000 15.00 75,000
2014-05-22 Wennogle Lawrence P. (Vice President, Drug Discovery) Sale 6,000 14.99 89,970
2014-02-05 Riggs Rory B (Director) Buy 28,571 17.50 499,992
2013-12-16 Wennogle Lawrence P. (Vice President, Drug Discovery) Option Ex 12,500 .30 3,750

Insider trading activities including stock purchases, stock sales, and option exercises of ITCI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Intra-cellular Thera38, Inc. (symbol ITCI, CIK number 1567514) see the Securities and Exchange Commission (SEC) website.